June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

Of the 289 patients in the study, 39 (13.5 %) were treatment-naïve. Table 1 summarizes key baseline characteristics of the treatment-naïve patients and study eyes. Eighteen patients were diagnosed ...

Please provide your email address to receive an email when new articles are posted on . According to Kuppermann, Steinert Endowed Professor and chair of the department of ophthalmology and visual ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

This supplement to The American Journal of Managed Care describes an economic evaluation of a fluocinolone acetonide (FAc) intravitreal implant for patients with diabetic macular edema (DME). The ...

This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, ...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BARCELONA, Spain — A subgroup analysis of the DAVIO 2 ...

At the American Academy of Ophthalmology (AAO) annual meeting, new data were presented from a 7-month analysis on OTX-TKI, an axitinib (Inlyta) intravitreal implant being evaluated for the treatment ...

Introduction: Diabetic macular edema (DME) is the most common cause of visual impairment in patients with diabetes. DME is a complex disease characterized by the deposition of fluid and proteins ...